Abstract:Although computational predictions of pharmacokinetics (PK) are desirable at the drug design stage, existing approaches are often limited by prediction accuracy and human interpretability. Using a discovery data set of mouse and rat PK studies at Roche (9,685 unique compounds), we performed a proof-of-concept study to predict key PK properties from chemical structure alone, including plasma clearance (CLp), volume of distribution at steady-state (Vss), and oral bioavailability (F). Ten machine learning (ML) models were evaluated, including Single-Task, Multitask, and transfer learning approaches (i.e., pretraining with in vitro data). In addition to prediction accuracy, we emphasized human interpretability of outcomes, especially the quantification of uncertainty, applicability domains, and explanations of predictions in terms of molecular features. Results show that intravenous (IV) PK properties (CLp and Vss) can be predicted with good precision (average absolute fold error, AAFE of 1.96-2.84 depending on data split) and low bias (average fold error, AFE of 0.98-1.36), with AutoGluon, Gaussian Process Regressor (GP), and ChemProp displaying the best performance. Driven by higher complexity of oral PK studies, predictions of F were more challenging, with the best AAFE values of 2.35-2.60 and higher overprediction bias (AFE of 1.45-1.62). Multi-Task approaches and pretraining of ChemProp neural networks with in vitro data showed similar precision to Single-Task models but helped reduce the bias and increase correlations between observations and predictions. A combination of GP-computed prediction variance, molecular clustering, and dimensionality-reduction provided valuable quantitative insights into prediction uncertainty and applicability domains. SHAPley Additive exPlanations (SHAPs) highlighted molecular features contributing to prediction outcomes of Vss, providing explanations that could aid drug design. Combined results show that computational predictions of PK are feasible at the drug design stage, with several ML technologies converging to successfully leverage historical PK data sets. Further studies are needed to unlock the full potential of this approach, especially with respect to data set sizes and quality, transfer learning between in vitro and in vivo data sets, model-independent quantification of uncertainty, and explainability of predictions.

Deep-PK: deep learning for small molecule pharmacokinetic and toxicity prediction

An Adaptive Graph Learning Method for Automated Molecular Interactions and Properties Predictions

pkCSM: Predicting Small-Molecule Pharmacokinetic and Toxicity Properties Using Graph-Based Signatures

DeepCt: Predicting pharmacokinetic concentration-time curves and compartmental models from chemical structure using deep learning

Machine learning framework to predict pharmacokinetic profile of small molecule drugs based on chemical structure

The Development and Application of KinomePro-DL: A Deep Learning Based Online Small Molecule Kinome Selectivity Profiling Prediction Platform

Actionable predictions of human pharmacokinetics at the drug design stage

Computational Predictions of Nonclinical Pharmacokinetics at the Drug Design Stage

A deep learning based multi-model approach for predicting drug-like chemical compound's toxicity

deepFPlearn +: enhancing toxicity prediction across the chemical universe using graph neural networks

DeepDrug: A General Graph-Based Deep Learning Framework for Drug-Drug Interactions and Drug-Target Interactions Prediction

Deep Learning Based Drug Metabolites Prediction

Deep Kernel Inversion: Rapid and Accurate Molecular Interaction Prediction for Drug Design

Interpretable deep-learning pKa prediction for small molecule drugs via atomic sensitivity analysis

Advanced graph and sequence neural networks for molecular property prediction and drug discovery

A Deep Neural Network -- Mechanistic Hybrid Model to Predict Pharmacokinetics in Rat

A Combination of Machine Learning and PBPK Modeling Approach for Pharmacokinetics Prediction of Small Molecules in Humans

Prediction Models for Agonists and Antagonists of Molecular Initiation Events for Toxicity Pathways Using an Improved Deep-Learning-Based Quantitative Structure–Activity Relationship System

PKSmart: An Open-Source Computational Model to Predict Pharmacokinetics of Small Molecules

A deep neural network: mechanistic hybrid model to predict pharmacokinetics in rat

QPowered Compound2DeNovoDrugPropMax –A Novel Programmatic Tool Incorporating Deep Learning and In Silico Methods for Automated In Silico Bio- Activity Discovery for any Compound of Interest